Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan P Sherlock

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Nature Medicine|September 9, 2011
Autoimmunity's collateral damage: Gut microbiota strikes 'back'Daniel J Cua, Jonathan P Sherlock
Rheumatology (Oxford, England)|October 20, 2021
Interleukin-23 in perspectiveJonathan P Sherlock, Daniel J Cua
Current Opinion in Pharmacology|April 2, 2013
Interleukin-23: a promising therapeutic target in seronegative spondyloarthropathyJonathan P Sherlock, Daniel J Cua
Molecular Immunology|August 6, 2013
The critical role of interleukin-23 in spondyloarthropathyJonathan P Sherlock, Christopher D Buckley, Daniel J Cua
Current Opinion in Rheumatology|November 22, 2014
The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseasesJonathan P Sherlock, Peter C Taylor, Christopher D Buckley
Arthritis Research & Therapy|April 26, 2022
The role of interleukin (IL)-23 in regulating pain in arthritisKevin M-C Lee, Jonathan P Sherlock, John A Hamilton
Lancet (London, England)|May 27, 2015
Spondyloarthropathy: interleukin 23 and disease modificationJonathan P Sherlock, Peter C Taylor, Christopher D Buckley, et al.
Arthritis Research & Therapy|May 4, 2013
What can rheumatologists learn from translational cancer therapy?Jonathan P Sherlock, Andrew D Filer, John D Isaacs, et al.
Nature Reviews. Rheumatology|November 14, 2018
Pathogenic stromal cells as therapeutic targets in joint inflammationStephanie G Dakin, Mark Coles, Jonathan P Sherlock, et al.
Nature Reviews. Rheumatology|December 1, 2018
Author Correction: Pathogenic stromal cells as therapeutic targets in joint inflammationStephanie G Dakin, Mark Coles, Jonathan P Sherlock, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Nature Medicine|September 9, 2011
Autoimmunity's collateral damage: Gut microbiota strikes 'back'Daniel J Cua, Jonathan P Sherlock
Rheumatology (Oxford, England)|October 20, 2021
Interleukin-23 in perspectiveJonathan P Sherlock, Daniel J Cua
Current Opinion in Pharmacology|April 2, 2013
Interleukin-23: a promising therapeutic target in seronegative spondyloarthropathyJonathan P Sherlock, Daniel J Cua
Molecular Immunology|August 6, 2013
The critical role of interleukin-23 in spondyloarthropathyJonathan P Sherlock, Christopher D Buckley, Daniel J Cua
Current Opinion in Rheumatology|November 22, 2014
The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseasesJonathan P Sherlock, Peter C Taylor, Christopher D Buckley
Arthritis Research & Therapy|April 26, 2022
The role of interleukin (IL)-23 in regulating pain in arthritisKevin M-C Lee, Jonathan P Sherlock, John A Hamilton
Lancet (London, England)|May 27, 2015
Spondyloarthropathy: interleukin 23 and disease modificationJonathan P Sherlock, Peter C Taylor, Christopher D Buckley, et al.
Arthritis Research & Therapy|May 4, 2013
What can rheumatologists learn from translational cancer therapy?Jonathan P Sherlock, Andrew D Filer, John D Isaacs, et al.
Nature Reviews. Rheumatology|November 14, 2018
Pathogenic stromal cells as therapeutic targets in joint inflammationStephanie G Dakin, Mark Coles, Jonathan P Sherlock, et al.
Nature Reviews. Rheumatology|December 1, 2018
Author Correction: Pathogenic stromal cells as therapeutic targets in joint inflammationStephanie G Dakin, Mark Coles, Jonathan P Sherlock, et al.
Pageof 2